2021-01-17Zeitschriftenartikel
SARS-CoV-2 prevalence and immunity: a hospital-based study from Malawi
dc.contributor.author | Meinus, C. | |
dc.contributor.author | Singer, R. | |
dc.contributor.author | Nandi, B. | |
dc.contributor.author | Jagot, O. | |
dc.contributor.author | Becker-Ziaja, B. | |
dc.contributor.author | Karo, B. | |
dc.contributor.author | Mvula, B. | |
dc.contributor.author | Jansen, A. | |
dc.contributor.author | Baumann, J. | |
dc.contributor.author | Schultz, A. | |
dc.date.accessioned | 2022-03-22T13:52:25Z | |
dc.date.available | 2022-03-22T13:52:25Z | |
dc.date.issued | 2021-01-17 | none |
dc.identifier.other | 10.1016/j.ijid.2021.12.336 | |
dc.identifier.uri | http://edoc.rki.de/176904/9534 | |
dc.description.abstract | Background: COVID-19 transmission and disease dynamics in sub-Saharan Africa are not well understood. Our study aims to provide insight into COVID-19 epidemiology in Malawi by estimating SARS-CoV-2 prevalence and immunity after SARS-CoV-2 infection in a hospital-based setting. Methods: We conducted a hospital-based, convenience sampling, cross-sectional survey for SARS-CoV-2 in Lilongwe, Malawi. Participants answered a questionnaire and were tested for SARS-CoV-2 by enzyme-linked immunosorbent assay and real-time reverse-transcription polymerase chain reaction (RT-PCR). A surrogate virus neutralization test (sVNT) was performed in seropositive samples to estimate immunity. Poisson regression was used to assess SARS-CoV-2 point prevalence association with demographic and behavioral variables. Findings: The study included 930 participants. We found a combined point prevalence of 10.1%. Separately analyzed, RT-PCR positivity was 2.0%, and seropositivity was 9.3%. Of tested seropositive samples, 90.1% were sVNT positive. We found a high rate (45.7%) of asymptomatic SARS-CoV-2 infection. SARS-CoV-2 point prevalence was significantly associated with being a healthcare worker. Interpretation: Our study suggests that official data underestimate COVID-19 transmission. Using sVNTs to estimate immunity in Malawi is feasible and revealed considerable post-infection immunity in our cohort. Subclinical infection and transmission are probably a game-changer in surveillance, mitigation and vaccination strategies. | eng |
dc.language.iso | eng | none |
dc.publisher | Robert Koch-Institut | |
dc.rights | (CC BY 3.0 DE) Namensnennung 3.0 Deutschland | ger |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/de/ | |
dc.subject | serosurvey | eng |
dc.subject | COVID-19 | eng |
dc.subject | prevalence | eng |
dc.subject | immunity | eng |
dc.subject | Malawi | eng |
dc.subject | Africa | eng |
dc.subject.ddc | 610 Medizin und Gesundheit | none |
dc.title | SARS-CoV-2 prevalence and immunity: a hospital-based study from Malawi | none |
dc.type | article | |
dc.identifier.urn | urn:nbn:de:0257-176904/9534-9 | |
dc.type.version | publishedVersion | none |
local.edoc.container-title | International Journal of Infectious Diseases | none |
local.edoc.container-issn | 0022-1899 | none |
local.edoc.type-name | Zeitschriftenartikel | |
local.edoc.container-type | periodical | |
local.edoc.container-type-name | Zeitschrift | |
local.edoc.container-url | https://www.sciencedirect.com/science/article/pii/S1201971221012340 | none |
local.edoc.container-publisher-name | Oxford University Press | none |
local.edoc.container-volume | 116 | none |
local.edoc.container-year | 2021 | none |
local.edoc.container-firstpage | 157 | none |
local.edoc.container-lastpage | 165 | none |
dc.description.version | Peer Reviewed | none |